Recidiving Venous Thrombosis Revealing an Antiphospholipid Syndrome Associated with a Leiden Mutation of Factor V: A Case Report

Raihane BAHRI^{1, 2,} , Mohamed Amine AZNAG^{1, 3}, Fadoua ELFARSSANI^{1, 2}, Siham KHAYATI^{1, 2}, Saida EDDYB^{1, 2}, Hicham YAHYAOUI^{1, 2}, Mustapha AIT AMEUR^{1, 2}, Mohamed ZIANI^{1, 3} and Mohamed CHAKOUR^{1, 2}

¹Faculty of Medicine and Pharmacy, Marrakesh, Morocco

²Departement of Hematology, Avicenna Military Hospital, Marrakesh, Morocco

³Departement of Internal Medicine, Avicenna Military Hospital, Marrakesh, Morocco

Cite this paper

Raihane BAHRI, Mohamed Amine AZNAG, Fadoua ELFARSSANI, Siham KHAYATI, Saida EDDYB, Hicham YAHYAOUI, Mustapha AIT AMEUR, Mohamed ZIANI and Mohamed CHAKOUR. Recidiving Venous Thrombosis Revealing an Antiphospholipid Syndrome Associated with a Leiden Mutation of Factor V: A Case Report. American Journal of Medical Case Reports. 2021; 9(6):318-320. doi: 10.12691/AJMCR-9-6-3

Abstract

Recurrent thrombosis is a common complication in various pathologies and is part of the definition of antiphospholipid syndrome. We report an observation in which the patient presented with repeated thrombosis, due not only to an antiphospholipid syndrome with partial thromboplastin time with normal activator, but also to a resistance to active protein C linked to the existence of the Leiden factor mutation V. This observation confirms the most often multifactorial nature of thromboses and therefore encourages the search for resistance to activated protein C before an evocative clinic, especially if the routine coagulation assessment is normal.

Keywords

leiden factor mutation V, thrombosis, antiphospholipid syndrome

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	Allaart CF, Poort SR, Rosendaal FR, Reitsma PH, Bertina RM, Bri&t E. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet 1993; 341: 134-8.
[2]	Svensson PJ, Dahlbsck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 5. 17-22.
[3]	Dahlback B. Resistance to activated protein C caused by the R506Q mutation in the gene for factor V is a common risk factor for venous thrombosis. J Intern Med Suppl 1997; 740: 1-8.
[4]	Montes MA, Fox EA, Longtine JA, Dorfman DM. Comparaison of functional testing for resistance to activated protein C and molecular biological testing for factor V R506Q in 307 patients. Arch Path01 Lab Med 1998; 122: 325-9.
[5]	Strobl FJ, Hoffman S, Huber S, Williams EC, Voelkerding KV Activated protein C resistance assay performance: improvement by sample dilution with factor V deficient plasma. Arch Path01 Lab Med 1998; 122: 430-3.
[6]	Bathelier C, Champenois T, Lucotte G. ARMS test for diagnosis of factor V Leiden mutation and allele frequencies in France. Mol Cell Probes 1998; 12: 121-3.
[7]	Guis-Sabatier S, Roudier J. Syndrome des antiphospholipides et mutation Leiden du facteur V. Trois cas de thrombophlébites récidivantes. Rev Rhum 2000; 67: 158-61.
[8]	Guermazi S, Znazen R. Résistance à la protéine C activée et facteur V Leiden : intérêt clinique. Pathologie Biologie. 2011; 59 : 281-5.
[9]	Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-4.
[10]	Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-8.
[11]	Walker ID, Greaves M, Preston FE, British Society for Haematology FE. Investigation and management of heritable thrombophilia. Guideline. Br J Haematol 2001; 114: 512-28.
[12]	Robert H, Thomas MD. Hypercoagulability Syndromes. Arch Intern Med 2001; 161: 2433-9.
[13]	Nojima J, Kuratsune H. Acquired activated protein C resistance associated with IgG antibodies against_2-glycoprotein i and prothrombin as a strong risk factor for venous thromboembolism. Clinical Chemistry 2005; 51 : 3545-52.
[14]	Male C, Mitchell L, Julian J, et al. Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 2001; 97: 844-9.
[15]	Cohen H, Hunt BJ, Efthymiou M, Arachchillage DR, Mackie IJ, Clawson S, et al. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol. 2016; 3: e426-36.
[16]	Haladyj E, Olesinska M. Rivaroxaban a safe therapeutic option in patients with antiphospholipid syndrome? Our experience in 23 cases. Reumatologia. 2016; 54: 146–9.
[17]	Malec K, Goralczyk T, Undas A. The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome. Thromb Res. 2017; 152: 93-7.
[18]	Signorelli F, Nogueira F, Domingues V, Mariz HA, Levy RA. Thrombotic events in Patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases. Clin Rheumatol. 2016; 35: 801-5.
[19]	Son M, Wypasek E, Celinska-Lowenhoff M, Undas A. The use of rivaroxaban in patients with antiphospholipid syndrome : a series of 12 cases. Thromb Res. 2015; 135: 1035-6.
[20]	Schaefer JK, McBane RD, Black DF, Williams LN, Moder KG, Wysokinski WE. Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. Thromb Haemost. 2014; 112: 947-50.
[21]	Crowley MP, Cuadrado MJ, Hunt BJ. Catastrophic antiphospholipid syndrome on switching from warfarin to rivaroxaban. Thromb Res. 2017; 153: 37-9.
[22]	Pengo V, Banzato A, Bison E, Zoppellaro G, Padayattil JS, Denas G. Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial. Lupus. 2016; 25: 301-6.